Studies of 4 to 6 months of treatment with interferon for hepatitis B e antigen (HBeAg)-positive chronic hepatitis B virus (HBV) infection have shown clearance of HBeAg to be higher in treated patients than it is in controls by approximately 25%. These results are considerably better than those with antiviral agents. Therefore, the recent European Association for the Study of the Liver (EASL) Consensus Committee recommended the use of interferon α for this condition. Treatment with pegylated interferons in several trials has shown better results still. Lamivudine in combination with interferon, however, did not improve the results at 6 months after the end of therapy. In HBeAg-negative chronic HBV infection, pegylated interferon α is superior to lamivudine, and, again, combination with lamivudine does not improve the results. Side effects in all studies have been tolerable. Thus, these observations in chronic HBV infection, whether HBeAg-positive or HBeAg-negative, suggest an important, even primary, role for pegylated interferon therapy.
KEYWORDS
Interferon - pegylated interferon alfa-2a (40 kD) - pegylated interferon alfa-2b (12 kD)
REFERENCES
-
1
Greenberg H B, Pollard R B, Lutwick L I et al..
Effect of human leukocyte interferon on hepatitis B virus infection in patients with chronic active hepatitis.
N Engl J Med.
1976;
295
517-522
-
2
Lok A S, Heathcote E J, Hoofnagle J H.
Management of hepatitis B: 2000. Summary of a workshop.
Gastroenterology.
2001;
120
1828-1853
-
3
EASL International Consensus Conference on Hepatitis B .
13-14 September, 2002: Geneva, Switzerland. Consensus statement (short version).
J Hepatol.
2003;
38
533-540
, (review)
-
4
Manns M P.
Current state of interferon therapy in the treatment of chronic hepatitis B.
Semin Liver Dis.
2002;
22(Suppl 1)
7-13
-
5
Conjeevaram H S, Lok A S-F.
Management of chronic hepatitis B.
J Hepatol.
2003;
38
S90-S103
-
6
Cooksley W G.
Treatment of hepatitis B with interferon and combination therapy.
Clin Liver Dis N Am.
2004;
, (In press)
-
7
Wong D K, Cheung A M, O'Rourke K et al..
Effect of α-interferon treatment in patients with hepatitis B e antigen-positive chronic hepatitis B. A meta-analysis.
Ann Intern Med.
1993;
119
312-323
-
8
Craxi A, Di Bona D, Camma C.
Interferon alpha for HBeAg positive chronic hepatitis B: systematic review.
J Hepatol.
2003;
39(Suppl 1)
99-105
-
9
Bortolotti F, Jara P, Barbera C et al..
Long term effect of alpha interferon in children with chronic hepatitis B.
Gut.
2000;
46
715-718
-
10
Fattovich G, Giustina G, Sanchez-Tapias J et al..
Delayed clearance of serum HBsAg in compensated cirrhosis B: relation to interferon alpha therapy and disease prognosis. European Concerted Action on Viral Hepatitis (EUROHEP).
Am J Gastroenterol.
1998;
93
896-900
-
11
Lau D T, Everhart J, Kleiner D E et al..
Long-term follow-up of patients with chronic hepatitis B treated with interferon alfa.
Gastroenterology.
1997;
113
1660-1667
-
12
Lin S M, Sheen I S, Chien R N et al..
Long-term beneficial effect of interferon therapy in patients with chronic hepatitis B virus infection.
Hepatology.
1999;
29
971-975
-
13
Lok A S, Chung H T, Liu V W, Ma O C.
Long-term follow-up of chronic hepatitis B patients treated with interferon alfa.
Gastroenterology.
1993;
105
1833-1838
-
14
Lok A SF, McMahon B J.
Chronic hepatitis B.
Hepatology.
2001;
34
1225-1241
-
15
Krogsgaard K.
The long-term effect of treatment with interferon-alpha 2a in chronic hepatitis B. The Long-Term Follow-up Investigator Group. The European Study Group on Viral Hepatitis (EURHEP) Executive Team on Anti-Viral Treatment.
J Viral Hepat.
1998;
5
389-397
-
16
Thomas H C, Lok A SF, Carreno V et al..
Comparative study of three doses of interferon alfa-2a in chronic active hepatitis B. The International Hepatitis Trial Group.
J Viral Hepat.
1994;
1
139-148
-
17
Janssen H L, Gerken G, Carreno V et al..
Interferon alpha for chronic hepatitis B infection: increased efficacy of prolonged treatment. The European Concerted Action on Viral Hepatitis (EUROHEP).
Hepatology.
1999;
30
238-243
-
18
Cohard M, Poynard T, Mathurin P et al..
Prednisone-interferon combination in the treatment of chronic hepatitis B: direct and indirect meta-analysis.
Hepatology.
1994;
20
1390-1398
-
19
Kao J H, Wu N H, Chen P J et al..
Hepatitis B genotypes and the response to interferon therapy.
J Hepatol.
2000;
33
998-1002
-
20
Zhang X, Zoulim F, Habersetzer F et al..
Analysis of hepatitis B virus genotypes and pre-core region variability during interferon treatment of HBe antigen negative chronic hepatitis B.
J Med Virol.
1996;
48
8-16
-
21
Hoofnagle J H, Di Bisceglie A M, Waggoner J G, Park Y.
Interferon alfa for patients with clinically apparent cirrhosis due to chronic hepatitis B.
Gastroenterology.
1993;
104
1116-1121
-
22
Perrillo R, Tamburro C, Regenstein F et al..
Low-dose, titratable interferon alfa in decompensated liver disease caused by chronic infection with hepatitis B virus.
Gastroenterology.
1995;
109
908-916
-
23
Janssen H L, Schalm S W, Berk L et al..
Repeated courses of alpha-interferon for treatment of chronic hepatitis type B.
J Hepatol.
1993;
17(Suppl 3)
S47-S51
-
24
Carreno V, Marcellin P, Hadziyannis S et al..
Retreatment of chronic hepatitis B e antigen-positive patients with recombinant interferon alfa-2a. The European Concerted Action on Viral Hepatitis (EUROHEP).
Hepatology.
1999;
30
277-282
-
25
Manesis E K, Hadziyannis S J.
Interferon alpha treatment and retreatment of hepatitis B e antigen-negative chronic hepatitis B.
Gastroenterology.
2001;
121
101-109
-
26
Brunetto M R, Oliveri F, Coco B et al..
The outcome of chronic anti-HBe positive chronic hepatitis B in alpha interferon treated and untreated patients: a long term cohort study.
J Hepatol.
2002;
36
263-270
-
27
Lampertico P, Del Ninno E, Manzin A et al..
A randomized controlled trial of a 24-month course of interferon alfa 2b in patients with chronic hepatitis B who had hepatitis B virus DNA without hepatitis B e antigen in serum.
Hepatology.
1997;
26
1621-1625
-
28
Papatheodoridis G V, Manesis E, Hadziyannis S J.
The long term outcome of interferon-alpha treated and untreated patients with HBeAg-negative chronic hepatitis B.
J Hepatol.
2001;
34
306-313
-
29
Oliveri F, Santantonio T, Bellati G et al..
Long term response to therapy of chronic anti-HBe-positive hepatitis B is poor independent of type and schedule of interferon.
Am J Gastroenterol.
1999;
94
1366-1372
-
30
Cooksley W GE, Lai M-Y, Piratvisuth T et al..
Peginterferon a-2a (40 kDa): an advance in the treatment of hepatitis B e antigen-positive chronic hepatitis B.
J Viral Hepat.
2003;
10
298-305
-
31
Cooksley W GE, Lai M-Y, Piratvisuth T et al..
Treatment with peginterferon alfa-2a (40kD) (Pegasys) results in improved rates of response compared to conventional interferon in patients with HBeAg positive chronic hepatitis B, including HBV genotypes B or “difficult to treat” genotype C.
J Hepatol.
2003;
38
52
, (abst)
-
32
Niederau C, Heintges T, Lange S et al..
Long-term follow-up HBeAg-positive patients treated with interferon alfa for chronic hepatitis B.
N Engl J Med.
1996;
334
1422-1427
-
33
Liaw Y-F, Chow W C, Shue K et al..
Effects of lamivudine on disease progression and development of liver cancer in advanced chronic hepatitis B: a prospective double-blind placebo-controlled clinical trial.
Hepatology.
2003;
38(Suppl 1)
262A
-
34 Hadziyannis S, Tassopoulos N, Heathcote J et al.. 96 weeks of adefovir dipivoxil in HBeAg negative chronic hepatitis B: significant virological, biochemical and histological improvement. Presented at the 11th International Symposium on Viral Hepatitis in Liver Disease April 5-8, 2003 Sydney, Australia;
-
35
Chang T T, Lim S G, Hadziyannis S et al..
Long-term safety of adefovir dipivoxil 10 mg once daily in chronic hepatitis B: an integrated analysis of two phase III studies.
J Hepatol.
2003;
38(Suppl 2)
133A
-
36
Mutimer D, Naoumov N, Honkoop P et al..
Combination alpha-interferon and lamivudine therapy for alpha-interferon-resistant chronic hepatitis B infection: results of a pilot study.
J Hepatol.
1998;
28
923-929
-
37
Schiff E R, Karayalcin S, Grimm I et al..
A placebo controlled study of lamivudine and interferon α-2b in patients with chronic hepatitis B who previously failed interferon therapy.
Hepatology.
1998;
28
388A
-
38
Schalm S W, Heathcote J, Cianciara J et al..
Lamivudine and alpha interferon combination treatment of patients with chronic hepatitis B infection: a randomised trial.
Gut.
2000;
46
562-568
-
39
Barbaro G, Zechini F, Pellicefli A M et al..
Long-term efficacy of alpha-2b and lamivudine in combination compared to lamivudine monotherapy in patients with hepatitis B. An Italian multicenter randomized trial.
J Hepatol.
2001;
35
406-411
-
40
Sanantonio T, Niro G A, Sinisi E et al..
Lamivudine/interferon combination therapy in anti-HBe positive chronic hepatitis B: a controlled pilot study.
J Hepatol.
2002;
36
799-804
-
41
Sung J JY, Chan H LY, Hui A Y et al..
Combination of pegylated interferon and lamivudine is superior to lamivudine monotherapy in the treatment of chronic hepatitis B-a randomized trial.
J Hepatol.
2003;
38(Suppl 2)
33A
-
42
Janssen H LA, Senturk H, Zeuzum S et al..
Peginterferon alfa-2b and lamivudine combination therapy compared with peginterferon alfa-2b for chronic HBeAg-positive hepatitis B: a randomized controlled trial in 307 patients.
Hepatology.
2003;
38(Suppl 1)
246A
-
43
Marcellin P, Lau G KK, Bonino F et al..
A phase III, partially double-blinded study evaluating the efficacy and safety of peginterferon alfa-2A (40kD) (Pegasys®) alone or in combination with lamvudine vs lamivudine in 546 patients with HBeAg-negative/anti-HBe-positive chronic hepatitis B.
Hepatology.
2003;
38(Suppl 1)
724A
-
44
Fried M W, Shiffman M L, Reddy K R et al..
Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection.
N Engl J Med.
2002;
347
975-982
Professor
Graham Cooksley
Department of Medicine, The University of Queensland
C8 Clinical Sciences Building, Royal Brisbane Hospital
Queensland, Australia 4029
Email: grahamC@qimr.edu.au
